Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04881019 · ClinicalTrials.gov registry record

PRediction Of Glycemic RESponse Study

A clinical trial of Glycemic Response, sponsored by Scripps Translational Science Institute.

Active
Registry status
1,070
Enrollment target
1
Study location

NCT04881019 is a study of Glycemic Response that is active but no longer recruiting, run by Scripps Translational Science Institute. The registered enrollment target is 1,070 participants, above the 51-participant average among 4 other Glycemic Response trials with a reported enrollment target (1998% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04881019, a study of Glycemic Response, is active but no longer recruiting, sponsored by Scripps Translational Science Institute.

ACTIVE NOT RECRUITING
Registry status
1,070 participants
Enrollment target
1
Study location

Study Summary

The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary intake, activity levels, and continuous glucose values over 10 days, link to clinical events out to 3-years, and use that data along with genomic, microbiome, electronic health record (EHR), and other biomarker data to develop a predictive model of individual glucose responses to nutrient intake in individuals with and without type 2 diabetes.

Conditions Studied

Interventions

  • DEVICE Continuous glucose monitoring

Study Locations (1)

California

  • Scripps Research Translational Institute - San Diego

Trial Details

FieldValue
Enrollment Target 1,070 participants
Start Date 2021-06-08
Est. Completion 2025-12-31

What the Registry Record Tells You About NCT04881019

The ClinicalTrials.gov registry entry for NCT04881019 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,070 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 51-participant average among 4 other Glycemic Response trials with a reported enrollment target (1998% higher). The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glycemic Response appearing as the primary indexed condition, and to 1 intervention - of which Continuous glucose monitoring is the first listed.

NCT04881019 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04881019 about?

NCT04881019 is a clinical study titled "PRediction Of Glycemic RESponse Study". The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary intake, activity levels, and continuous glucose values over 10 days, link to clinical events out to 3-years, and use that data along with genomic, microbiome, electronic health record (EHR), and other biomarker da...

What is the current status of trial NCT04881019?

This trial is currently active not recruiting. The enrollment target is 1,070 participants. The study started on 2021-06-08. Estimated completion is 2025-12-31.

What conditions does trial NCT04881019 study?

This clinical trial studies the following conditions: Glycemic Response.

What interventions are being tested in trial NCT04881019?

The interventions under investigation include: Continuous glucose monitoring (DEVICE).

Who is sponsoring clinical trial NCT04881019?

This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04881019 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glycemic Response

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.